Geron Corp (NASDAQ:GERN) reported its fourth quarter and full-year 2025 financial results, delivering revenue growth from its newly launched drug but falling short of Wall Street's expectations on the top line. The market's immediate reaction was sharply negative, with shares tumbling nearly 10% in pre-market trading following the announcement.
Earnings Miss Drives Sell-Off
The core financial metrics for the quarter disappointed analysts, leading to a significant downward move in the stock price. The company's reported figures came in below consensus estimates on both revenue and earnings per share.
- Revenue: Geron reported Q4 2025 net product revenue of $48.0 million from its drug RYTELO® (imetelstat). This missed the analyst estimate of approximately $51.4 million.
- Earnings Per Share (EPS): The company reported a non-GAAP net loss per share of $0.03 for the quarter. This was slightly better than the estimated loss of $0.0323, but the revenue shortfall appears to have been the primary focus for investors.
The pre-market decline of nearly 10% suggests the market is penalizing the company for the revenue miss, indicating that sales execution or initial uptake of RYTELO may be a key concern for shareholders.
Full-Year 2025 Results and Business Highlights
Despite the quarterly miss, the company highlighted full-year achievements. For 2025, Geron generated $184 million in net product revenue from RYTELO, marking its first full year of sales following the drug's launch for lower-risk myelodysplastic syndromes (MDS). The company also noted that its total operating expenses for the year were $255 million, which fell within its previously provided guidance range, demonstrating cost management alongside its commercial rollout.
The press release emphasized the commercial progress of RYTELO, which remains Geron's sole commercial product and the central driver of its valuation. The company's ongoing pivotal Phase III trial of imetelstat in myelofibrosis represents its most significant near-term pipeline catalyst.
Looking Ahead: Estimates for 2026
While the press release did not provide formal financial guidance for 2026, current analyst estimates offer a benchmark for future performance. The market will be closely watching to see if Geron can meet or exceed these projections in the coming year.
- Q1 2026 Estimates: Analysts are forecasting a revenue of approximately $53.6 million and a non-GAAP EPS loss of $0.026.
- Full-Year 2026 Estimates: For the entire year, the consensus sales estimate stands at about $247.4 million, with an expected non-GAAP EPS loss of $0.046.
Achieving these sales estimates will be critical for rebuilding investor confidence after the Q4 revenue shortfall. The sequential growth implied by these numbers will be a key metric to monitor in subsequent quarters.
Recent Stock Performance Context
The sharp pre-market drop contrasts with the stock's recent positive trend. Prior to the earnings release, Geron shares had shown considerable strength:
- Up approximately 42% over the past month.
- Up about 21% over the past two weeks.
This context suggests that expectations heading into the earnings report were elevated, potentially amplifying the negative reaction to the revenue miss. The sell-off represents a significant reversal of the recent bullish momentum.
Conclusion
Geron's fourth quarter presents a mixed picture: solid initial annual sales for its flagship drug but a stumble in meeting quarterly revenue expectations. The market's severe reaction underscores the high stakes for commercial-stage biotech companies, where quarterly sales figures are scrutinized as the primary validation of a drug's market potential. The focus now shifts to the company's ability to accelerate RYTELO's adoption and execute on its clinical development plans to justify its valuation.
For a detailed look at Geron's historical earnings and future analyst estimates, you can review the data here.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation to buy or sell any security, or an endorsement of any investment strategy. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.